Barrington Research reaffirmed their market perform rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a report issued on Wednesday, MarketBeat.com reports.
Several other equities research analysts have also commented on the company. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $1.55.
View Our Latest Stock Analysis on OPKO Health
OPKO Health Stock Performance
OPKO Health (NASDAQ:OPK – Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm’s revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.10) earnings per share. As a group, research analysts forecast that OPKO Health will post -0.27 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Abel Hall LLC acquired a new position in shares of OPKO Health in the 1st quarter worth approximately $38,000. OP Asset Management Ltd acquired a new position in shares of OPKO Health in the 1st quarter worth approximately $1,257,000. Apella Capital LLC acquired a new position in shares of OPKO Health in the 1st quarter worth approximately $34,000. SG Americas Securities LLC grew its position in shares of OPKO Health by 62.6% in the 1st quarter. SG Americas Securities LLC now owns 87,846 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 33,824 shares in the last quarter. Finally, World Investment Advisors grew its position in shares of OPKO Health by 63.8% in the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 25,902 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.
More OPKO Health News
Here are the key news stories impacting OPKO Health this week:
- Positive Sentiment: Company highlighted clinical progress: ModeX advancing five clinical programs and OPKO completed the first dose cohort of MDX2301 Phase 1 (tetravalent bispecific antibody for COVID-19), which supports longer‑term pipeline value. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs
- Positive Sentiment: Q1 R&D/operational milestones were emphasized on the earnings call and press release, signaling continued pipeline activity that could drive long‑term value if programs advance. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
- Neutral Sentiment: EPS was in line with consensus at a loss of $0.07, roughly flat-to-improved versus prior year loss, which reduces surprise risk on profitability for the quarter. OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
- Neutral Sentiment: Analyst coverage remains conservative: Barrington Research reaffirmed a “market perform” rating, indicating limited near‑term upside from existing analyst views. Benzinga coverage note
- Negative Sentiment: Revenue missed expectations: Q1 revenue was ~$124.2M vs. analyst estimates near $130.5M, with reports noting year‑over‑year declines (company/press references include declines as large as ~25.7% reflecting a smaller BioReference diagnostics base). This top‑line weakness is the primary near‑term concern. OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
- Negative Sentiment: Guidance came in slightly light: FY‑2026 revenue range of ~$530M–$560M and Q2 revenue guidance of $127M–$132M are at or below consensus (Q2 consensus ~ $135.7M; FY midpoint below some Street estimates), which likely pressured sentiment around near‑term growth. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs
- Negative Sentiment: High intraday volume and negative margin/ROE metrics underline investor concern about near‑term profitability and declining diagnostic revenues contributing to the slowdown. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
About OPKO Health
OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Recommended Stories
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
